05: The Future of Psychedelics in Healthcare

The World as You’ll Know It: The Future Of Aging

Content provided by Aventine. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Aventine or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

3y ago 28:26

MP3•Episode home

Judith Warner speaks with Dr. Matthew Johnson about the state of psychedelic research today and the likelihood that certain drugs — MDMA and psilocybin specifically — could soon be approved for the treatment of conditions like addiction and PTSD. Psychedelics have long been known for their abilities to alter perception, but renewed interest by major research institutions in psychedelics’ ability to treat a range of common disorders has brought some of them to the precipice of FDA approval.

DR. JOHNSON is a professor of Psychiatry and Behavioral Sciences at Johns Hopkins University and a leader in the study of psychedelics for the treatment of addiction.

A transcript of their conversation can be found at Aventine.org/podcast.

To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy

Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

44 episodes

#Aventine Research Institute #Tech #Kurt Andersen